Arthur He
Stock Analyst at HC Wainwright & Co.
(3.90)
# 665
Out of 5,045 analysts
55
Total ratings
45.9%
Success rate
13.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arthur He
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADAG Adagene | Maintains: Buy | $8 → $7 | $1.92 | +264.58% | 11 | Aug 15, 2025 | |
| LVTX LAVA Therapeutics | Maintains: Neutral | $1.5 → $1.24 | $1.63 | -23.93% | 11 | Aug 5, 2025 | |
| AUPH Aurinia Pharmaceuticals | Assumes: Buy | $17 | $12.12 | +40.26% | 1 | Jul 30, 2025 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $6.5 → $120 | $62.80 | +91.08% | 4 | Jun 24, 2025 | |
| SLDB Solid Biosciences | Reiterates: Buy | $20 | $5.31 | +276.65% | 10 | Jun 17, 2025 | |
| VERA Vera Therapeutics | Maintains: Buy | $75 → $85 | $29.67 | +186.48% | 2 | Jun 2, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $4.35 | - | 8 | May 20, 2025 | |
| BCAB BioAtla | Reiterates: Neutral | n/a | $0.69 | - | 8 | Mar 31, 2025 |
Adagene
Aug 15, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $1.92
Upside: +264.58%
LAVA Therapeutics
Aug 5, 2025
Maintains: Neutral
Price Target: $1.5 → $1.24
Current: $1.63
Upside: -23.93%
Aurinia Pharmaceuticals
Jul 30, 2025
Assumes: Buy
Price Target: $17
Current: $12.12
Upside: +40.26%
Nektar Therapeutics
Jun 24, 2025
Maintains: Buy
Price Target: $6.5 → $120
Current: $62.80
Upside: +91.08%
Solid Biosciences
Jun 17, 2025
Reiterates: Buy
Price Target: $20
Current: $5.31
Upside: +276.65%
Vera Therapeutics
Jun 2, 2025
Maintains: Buy
Price Target: $75 → $85
Current: $29.67
Upside: +186.48%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.35
Upside: -
BioAtla
Mar 31, 2025
Reiterates: Neutral
Price Target: n/a
Current: $0.69
Upside: -